Acumen Pharmaceuticals
ABOS
69 hedge funds and large institutions have $61.1M invested in Acumen Pharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 9 increasing their positions, 27 reducing their positions, and 15 closing their positions.
1,500% more call options, than puts
Call options by funds: $48K | Put options by funds: $3K
40% more capital invested
Capital invested by funds: $43.6M → $61.1M (+$17.5M)
3% less funds holding
Funds holding: 71 → 69 (-2)
3.11% less ownership
Funds ownership: 62.1% → 58.99% (-3.1%)
13% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 15
67% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 27
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$684K |
| 2 |
SG Americas Securities
New York
|
+$559K |
| 3 |
Renaissance Technologies
New York
|
+$467K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$108K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$104K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$1.87M |
| 2 |
Franklin Resources
San Mateo,
California
|
-$1.07M |
| 3 |
YIH
Y-Intercept (HK)
Hong Kong
|
-$291K |
| 4 |
Pathstone Holdings
Englewood,
New Jersey
|
-$276K |
| 5 |
Goldman Sachs
New York
|
-$260K |
ABOS Hedge Fund Activity: Q3 2025 in Review
69 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in Acumen Pharmaceuticals (ABOS) for Q3 2025, worth a combined $61.1M — up 40% from $43.6M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of ABOS and 13 opened new positions — a net loss of 2 holders — while 27 trimmed existing stakes and 9 added.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $684K. The largest seller was Millennium Management, cutting an estimated $1.87M.
- 69 institutional investors held Acumen Pharmaceuticals (ABOS) as of Q3 2025, down from 71 in Q2 2025.
- Funds reported $61.1M of Acumen Pharmaceuticals stock for Q3 2025, up 40% quarter-over-quarter.
- 13 funds opened new Acumen Pharmaceuticals positions in Q3 2025 and 15 closed out, a net change of -2 holders.
- The largest Acumen Pharmaceuticals buyer in Q3 2025 was Citadel Advisors, an estimated $684K added.
- The largest Acumen Pharmaceuticals seller in Q3 2025 was Millennium Management, an estimated $1.87M sold.
Based on aggregated 13F filings for Q3 2025.